Business Context and Reporting Period
This Form 8-K reports on the annual meeting of stockholders held by IMMUNIC, INC. on June 28, 2023. The company is incorporated in Delaware and its common stock trades on The Nasdaq Stock Market LLC under the symbol IMUX.
Key Financial Metrics
This filing is a current report regarding corporate governance and does not contain financial performance data. Consequently, there are no reported values for revenue, profit, cash flow, margins, debt, or liquidity in this document.
Material Changes and Voting Results
Stockholders voted on three proposals at the meeting. A total of 25,616,356 shares were present, constituting a quorum out of 44,403,838 shares entitled to vote.
- Proposal 1: Election of Directors
- Dr. Richard Rudick: Elected with 19,855,497 votes FOR, 109,841 WITHHELD, and 5,651,018 BROKER NON-VOTES.
- Ms. Maria Törnsén: Elected with 19,840,786 votes FOR, 124,552 WITHHELD, and 5,651,018 BROKER NON-VOTES.
- Both directors were elected for a three-year term expiring at the 2026 annual meeting.
- Proposal 2: Ratification of Auditors
- Baker Tilly Virchow Krause, LLP was ratified as the independent registered public accounting firm for the fiscal year ending December 31, 2023.
- Votes: 25,469,440 FOR, 75,616 AGAINST, 71,300 ABSTAIN.
- Proposal 3: Amendments to 2019 Omnibus Plan
- Approved amendments to increase the number of common stock authorized for issuance by 4,440,000 shares, bringing the total to 10,348,871 shares.
- Approved the removal of the "evergreen" provision that previously allowed for automatic annual increases in authorized shares.
- Votes: 19,529,897 FOR, 408,815 AGAINST, 26,626 ABSTAIN.
Guidance, Outlook, and Risks
The filing text does not provide management commentary, financial guidance, outlook, or specific risk factors beyond the standard disclosure of the voting results.
Investor Verification Checklist
- Verify the updated total number of shares authorized for issuance under the 2019 Omnibus Plan (10,348,871 shares).
- Confirm the removal of the "evergreen" provision in the equity incentive plan, which may impact future share dilution mechanics.
- Review the tenure of the newly elected directors (Dr. Rudick and Ms. Törnsén) through the 2026 annual meeting.
- Check subsequent filings (e.g., 10-K or 10-Q) for the actual financial performance metrics absent from this 8-K.